JP2020534274A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534274A5 JP2020534274A5 JP2020515077A JP2020515077A JP2020534274A5 JP 2020534274 A5 JP2020534274 A5 JP 2020534274A5 JP 2020515077 A JP2020515077 A JP 2020515077A JP 2020515077 A JP2020515077 A JP 2020515077A JP 2020534274 A5 JP2020534274 A5 JP 2020534274A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- pharmaceutical composition
- hydrogen
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- -1 cyano, formyl Chemical group 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical group SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 206010048962 Brain oedema Diseases 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 1
- 125000005127 aryl alkoxy alkyl group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000005015 aryl alkynyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000005963 oxadiazolidinyl group Chemical group 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 150000003573 thiols Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 0 BC(*)(*C)N(C(*)C1(C)*)C1=O Chemical compound BC(*)(*C)N(C(*)C1(C)*)C1=O 0.000 description 12
- KQUQJHZJTWYGAQ-UHFFFAOYSA-N C(C1CCNCC1)N1CCCCC1 Chemical compound C(C1CCNCC1)N1CCCCC1 KQUQJHZJTWYGAQ-UHFFFAOYSA-N 0.000 description 1
- XPDSXKIDJNKIQY-UHFFFAOYSA-N C(CC1)CCC1N1CCNCC1 Chemical compound C(CC1)CCC1N1CCNCC1 XPDSXKIDJNKIQY-UHFFFAOYSA-N 0.000 description 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N C(CC1)CCN1C1CCNCC1 Chemical compound C(CC1)CCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 1
- FKYVHDSPGMMDFF-UHFFFAOYSA-N C(CN1CCCCC1)C1CCNCC1 Chemical compound C(CN1CCCCC1)C1CCNCC1 FKYVHDSPGMMDFF-UHFFFAOYSA-N 0.000 description 1
- LKUAPSRIYZLAAO-UHFFFAOYSA-N C(CN1CCNCC1)c1ccccc1 Chemical compound C(CN1CCNCC1)c1ccccc1 LKUAPSRIYZLAAO-UHFFFAOYSA-N 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N C(c1ccccc1)N1CCNCC1 Chemical compound C(c1ccccc1)N1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- CDGJGXXSONVEFL-ANLCFORVSA-N C=C[C@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)N([C@H](COCc2ccccc2)C(C2CCN(CN3CCCCC3)CC2)=O)C1=O Chemical compound C=C[C@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)N([C@H](COCc2ccccc2)C(C2CCN(CN3CCCCC3)CC2)=O)C1=O CDGJGXXSONVEFL-ANLCFORVSA-N 0.000 description 1
- IFDLFCDWOFLKEB-UHFFFAOYSA-N CCC(C)Cc1ccccc1 Chemical compound CCC(C)Cc1ccccc1 IFDLFCDWOFLKEB-UHFFFAOYSA-N 0.000 description 1
- OCKPCBLVNKHBMX-UHFFFAOYSA-N CCCCc1ccccc1 Chemical compound CCCCc1ccccc1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 description 1
- CTXVGAPEUMTYNI-BEMMEUOBSA-N CN(Cc1cc(C(F)(F)F)ccc1)C([C@@H](CC(N(CC1)CCC1N1CCCCC1)=O)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)C=C)C1=O)=O Chemical compound CN(Cc1cc(C(F)(F)F)ccc1)C([C@@H](CC(N(CC1)CCC1N1CCCCC1)=O)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)C=C)C1=O)=O CTXVGAPEUMTYNI-BEMMEUOBSA-N 0.000 description 1
- FJUKOXWSIGULLE-VZFXNNIISA-N C[C@H](c1ccccc1)NC(C(CC(N(CC1)CCC1N1CCCCC1)=O)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)/C=C/c2ccccc2)C1=O)=O Chemical compound C[C@H](c1ccccc1)NC(C(CC(N(CC1)CCC1N1CCCCC1)=O)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)/C=C/c2ccccc2)C1=O)=O FJUKOXWSIGULLE-VZFXNNIISA-N 0.000 description 1
- VBXHSGJTMUBAJO-AFAPVMNMSA-N C[C@H](c1ccccc1)NC([C@@H](CC(N(CC1)CCC1N1CCCCC1)=O)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)/C=C/c2cccc(I)c2)C1=O)=O Chemical compound C[C@H](c1ccccc1)NC([C@@H](CC(N(CC1)CCC1N1CCCCC1)=O)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)/C=C/c2cccc(I)c2)C1=O)=O VBXHSGJTMUBAJO-AFAPVMNMSA-N 0.000 description 1
- KKIMDKMETPPURN-UHFFFAOYSA-N FC(c1cccc(N2CCNCC2)c1)(F)F Chemical compound FC(c1cccc(N2CCNCC2)c1)(F)F KKIMDKMETPPURN-UHFFFAOYSA-N 0.000 description 1
- CJNRGSHEMCMUOE-UHFFFAOYSA-N NCCN1CCCCC1 Chemical compound NCCN1CCCCC1 CJNRGSHEMCMUOE-UHFFFAOYSA-N 0.000 description 1
- MSLWUURVHWDPBY-UQENTHRZSA-N O=C([C@@H](COCc1ccccc1)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)/C=C/c2ccccc2)C1=O)C1CCN(CCN2CCCCC2)CC1 Chemical compound O=C([C@@H](COCc1ccccc1)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)/C=C/c2ccccc2)C1=O)C1CCN(CCN2CCCCC2)CC1 MSLWUURVHWDPBY-UQENTHRZSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023161532A JP7699634B2 (ja) | 2017-09-15 | 2023-09-25 | 脳損傷を治療するための組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762559113P | 2017-09-15 | 2017-09-15 | |
| US62/559,113 | 2017-09-15 | ||
| US201762584343P | 2017-11-10 | 2017-11-10 | |
| US62/584,343 | 2017-11-10 | ||
| US201862658758P | 2018-04-17 | 2018-04-17 | |
| US62/658,758 | 2018-04-17 | ||
| PCT/US2018/051331 WO2019055913A1 (en) | 2017-09-15 | 2018-09-17 | COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023161532A Division JP7699634B2 (ja) | 2017-09-15 | 2023-09-25 | 脳損傷を治療するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020534274A JP2020534274A (ja) | 2020-11-26 |
| JP2020534274A5 true JP2020534274A5 (https=) | 2021-10-28 |
Family
ID=65723435
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515077A Pending JP2020534274A (ja) | 2017-09-15 | 2018-09-17 | 脳損傷を治療するための組成物及び方法 |
| JP2023161532A Active JP7699634B2 (ja) | 2017-09-15 | 2023-09-25 | 脳損傷を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023161532A Active JP7699634B2 (ja) | 2017-09-15 | 2023-09-25 | 脳損傷を治療するための組成物及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11628160B2 (https=) |
| EP (1) | EP3681871A4 (https=) |
| JP (2) | JP2020534274A (https=) |
| KR (1) | KR102790657B1 (https=) |
| CN (1) | CN111295373B (https=) |
| AU (1) | AU2018333051B2 (https=) |
| BR (1) | BR112020005107A2 (https=) |
| CA (1) | CA3075759A1 (https=) |
| IL (1) | IL273228B2 (https=) |
| MX (1) | MX2020002762A (https=) |
| MY (1) | MY208313A (https=) |
| TW (1) | TW201919625A (https=) |
| WO (1) | WO2019055913A1 (https=) |
| ZA (1) | ZA202001880B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012003436A1 (en) | 2010-07-01 | 2012-01-05 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| NZ724718A (en) | 2014-03-28 | 2023-04-28 | Azevan Pharmaceuticals Inc | Compositions and methods for treating neurodegenerative diseases |
| CN108883104A (zh) * | 2016-03-30 | 2018-11-23 | 森泰克希斯公司 | 用于在治疗成熟脑损伤中使用的mGluR5的负性变构调节剂 |
| WO2019055913A1 (en) | 2017-09-15 | 2019-03-21 | Azevan Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY |
| US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
| WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
| CN115350186A (zh) * | 2022-08-31 | 2022-11-18 | 中国人民解放军军事科学院军事医学研究院 | Sxr246在制备治疗创伤性脑损伤及预后不良药物中的应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| US4314081A (en) | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
| US4576753A (en) | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
| GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US4341698A (en) | 1979-06-21 | 1982-07-27 | Richardson-Merrell Inc. | Enkaphalin derivatives |
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| JPS6033439B2 (ja) | 1980-03-07 | 1985-08-02 | 財団法人相模中央化学研究所 | ジペプチドの製造方法 |
| JPS56125361A (en) | 1980-03-07 | 1981-10-01 | Sagami Chem Res Center | Azetidinone compound |
| FR2508035A1 (fr) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
| US4761501A (en) | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
| US4751299A (en) | 1983-11-18 | 1988-06-14 | Takeda Chemical Industries, Ltd. | Optically active β-lactams and method of their production |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4734498A (en) | 1986-07-10 | 1988-03-29 | Eli Lilly And Company | 3β-succinimidoazetidinones as chiral intermediates |
| US4772694A (en) | 1986-07-24 | 1988-09-20 | Eli Lilly And Company | Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| WO1992005784A1 (en) | 1990-10-02 | 1992-04-16 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
| GB9204001D0 (en) | 1992-02-25 | 1992-04-08 | Jacobs Suchard Ag | Process for producing reduced fat nuts |
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| AU4713293A (en) | 1992-07-13 | 1994-01-31 | Merck Sharp & Dohme Limited | Heterocyclic amide derivatives as tachykinin derivatives |
| EP0655055B1 (en) | 1992-08-13 | 2000-11-29 | Warner-Lambert Company | Tachykinin antagonists |
| FR2696178B1 (fr) | 1992-09-30 | 1994-12-30 | Sanofi Elf | Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
| ATE158580T1 (de) | 1993-05-06 | 1997-10-15 | Merrell Pharma Inc | Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5759865A (en) | 1995-05-03 | 1998-06-02 | Eli Lilly And Company | Combinatorial process for synthesizing azetidinone analogs |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| EP0939632B1 (en) | 1996-02-23 | 2005-10-05 | Eli Lilly And Company | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS |
| HUP0000288A3 (en) | 1996-12-13 | 2001-04-28 | Lilly Co Eli | Azetidinone derivatives as inhibitors of the enzymatic activity of psa, intermediates, process for their preparation and pharmaceutical compositions thereof |
| CA2285343A1 (en) * | 1997-03-31 | 1998-10-08 | Wakamoto Pharmaceutical Co., Ltd. | Biphenyl derivatives and medicinal compositions |
| DE69826487T2 (de) | 1997-07-30 | 2005-12-01 | Wyeth | Trizyclische vasopressin-agonisten |
| US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| AU749505B2 (en) | 1997-10-27 | 2002-06-27 | Dr. Reddy's Laboratories Limited | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| ES2258980T3 (es) | 1999-08-16 | 2006-09-16 | Revaax Pharmaceuticals Llc | Composiciones farmaceuticas que comprenden acido clavulanico o derivados del mismo para el tratamiento de trastornos del comportamiento. |
| GB0019006D0 (en) | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
| ES2666188T3 (es) | 2001-10-12 | 2018-05-03 | Azevan Pharmaceuticals, Inc. | Antagonistas del v1a de vasopresina beta-lactámicos |
| AU2002359761A1 (en) | 2001-12-18 | 2003-06-30 | Invenux, Inc. | Antibiotic compounds |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| GB0224919D0 (en) | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
| US7132426B2 (en) | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2005035492A1 (en) | 2003-10-03 | 2005-04-21 | Serenix Pharmaceuticals, Llc. | 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| EP1669776A1 (de) | 2004-12-11 | 2006-06-14 | Leica Geosystems AG | Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät |
| FR2881744B1 (fr) | 2005-02-09 | 2007-04-27 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique |
| AU2006227199A1 (en) | 2005-03-22 | 2006-09-28 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids for treating premenstrual disorders |
| CA2608718A1 (en) | 2005-05-18 | 2006-11-23 | Pfizer Limited | 1, 2, 4-triazole derivatives as vasopressin antagonists |
| KR101523776B1 (ko) * | 2005-07-19 | 2015-05-28 | 아제반 파마슈티칼스, 인코퍼레이티드 | 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질 |
| WO2007109615A2 (en) | 2006-03-21 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS |
| WO2008034032A2 (en) | 2006-09-14 | 2008-03-20 | Azevan Pharmaceuticals, Inc. | Beta-lactam cannabinoid receptor modulators |
| ATE532786T1 (de) | 2006-09-22 | 2011-11-15 | Janssen Pharmaceutica Nv | Spirobenzazepine als vasopressinantagonisten |
| CA2665851A1 (en) | 2006-09-22 | 2008-03-27 | Janssen Pharmaceutica N.V. | Spiro benzazepines as vasopressin antagonists |
| US8362037B2 (en) | 2007-03-23 | 2013-01-29 | Array Biopharma, Inc. | 2-aminopyridine analogs as glucokinase activators |
| FR2927625B1 (fr) | 2008-02-19 | 2010-03-12 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique |
| FR2930249B1 (fr) | 2008-04-21 | 2010-05-14 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. |
| WO2012003436A1 (en) | 2010-07-01 | 2012-01-05 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| CN102156420B (zh) | 2010-12-23 | 2012-11-07 | 天津职业技术师范大学 | 加快从计算机下载数据到单片机目标存储器的装置 |
| WO2014127350A1 (en) * | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| NZ724718A (en) | 2014-03-28 | 2023-04-28 | Azevan Pharmaceuticals Inc | Compositions and methods for treating neurodegenerative diseases |
| WO2019055913A1 (en) * | 2017-09-15 | 2019-03-21 | Azevan Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY |
-
2018
- 2018-09-17 WO PCT/US2018/051331 patent/WO2019055913A1/en not_active Ceased
- 2018-09-17 CA CA3075759A patent/CA3075759A1/en active Pending
- 2018-09-17 MX MX2020002762A patent/MX2020002762A/es unknown
- 2018-09-17 TW TW107132685A patent/TW201919625A/zh unknown
- 2018-09-17 MY MYPI2020001313A patent/MY208313A/en unknown
- 2018-09-17 US US16/646,744 patent/US11628160B2/en active Active
- 2018-09-17 JP JP2020515077A patent/JP2020534274A/ja active Pending
- 2018-09-17 KR KR1020207010875A patent/KR102790657B1/ko active Active
- 2018-09-17 EP EP18855876.1A patent/EP3681871A4/en active Pending
- 2018-09-17 AU AU2018333051A patent/AU2018333051B2/en active Active
- 2018-09-17 BR BR112020005107-1A patent/BR112020005107A2/pt unknown
- 2018-09-17 IL IL273228A patent/IL273228B2/en unknown
- 2018-09-17 CN CN201880070936.8A patent/CN111295373B/zh active Active
-
2020
- 2020-03-24 ZA ZA2020/01880A patent/ZA202001880B/en unknown
-
2023
- 2023-04-17 US US18/135,225 patent/US20240115553A1/en not_active Abandoned
- 2023-09-25 JP JP2023161532A patent/JP7699634B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534274A5 (https=) | ||
| JP2007519631A5 (https=) | ||
| JP2006524222A5 (https=) | ||
| CY1109493T1 (el) | Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις | |
| SA518391518B1 (ar) | مشتقات n-] 2-(1- بنزيل ببريدين-4-يل) إيثيل[ -4-(بيرازين-2-يل)-ببرازين-1- كربوكساميد ومركبات متصلة بها كمضادات مستقبلة المسكارين 4 (m4) لمعالجة أمراض عصبية | |
| RU2010138577A (ru) | ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3 | |
| TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
| JP2004520324A5 (https=) | ||
| JP2006524225A5 (https=) | ||
| CO5550451A2 (es) | Derivados de 3-(sulfonamidoetil)-indol para uso como mimeti- cos de glucocorticoides en el tratamiento de enfermedades inflamatorias, alergicas y proliferativas | |
| HRP20180199T1 (hr) | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1) | |
| RU2010137115A (ru) | Производные 5,6-бисарил-2-пиридинкарбоксамидов, способ их получения и их применение в терапии в качестве антагонистов рецепторов | |
| JP2015522650A5 (https=) | ||
| TW200633698A (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| HRP20140884T1 (hr) | Derivati fenoksipiridinilamida i njihova primjena u lijeäśenju bolesnih stanja posredovanih inhibitorima pde4 | |
| RU2015116816A (ru) | Производное имидазола | |
| ATE455756T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| JP2022501434A5 (https=) | ||
| RU2016138349A (ru) | Композиции и способы лечения нейродегенеративных заболеваний | |
| JP2010536821A5 (https=) | ||
| JP2005506982A5 (https=) | ||
| JP2017510645A5 (https=) | ||
| RU2014144951A (ru) | Новое 1-замещенное производное индазола | |
| JP2009502788A5 (https=) | ||
| CY1111744T1 (el) | Τροποποιητες της δραστηριοτητας toy υποδοχεα χημειοκινων, κρυσταλλικες μορφες και διεργασια |